Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TTOO BARDA Contract: Advance Technology for Diagnosis and Treatment of Bloodstream Infections. Update is pending any time.
https://www.t2biosystems.com/products-technology/pipeline/barda/
Go to T2 Biosystems products, etc. https://www.t2biosystems.com
$TTOO News: New FDA 510(k) Clearance Modernization Process
T2 Biosystems is awaiting FDA/HHS update on product in pipeline.
>>> https://www.medtechdive.com/news/fda-draft-guidance-510k-clearance-modernization/692952/ https://www.t2 biosystems.com
$TTOO News: New FDA 510(k) Clearance Modernization Process
T2 Biosystems is awaiting FDA/HHS update on product in pipeline.
>>> https://www.medtechdive.com/news/fda-draft-guidance-510k-clearance-modernization/692952/ https://www.t2 biosystems.com
$TTOO Today is World Sepsis Day #worldsepsisday
T2 Biosystems Products fight Sepsis and Bio-Threats.
T2 awaiting FDA/HHS news on new pipeline products.
For accurate DD, go to https://www.t2biosystems.com
and read https://www.t2biosystems.com/world-sepsis/
$TTOO Today is World Sepsis Day #worldsepsisday
T2 Biosystems Products fight Sepsis and Bio-Threats.
T2 awaiting FDA/HHS news on new pipeline products.
For accurate DD, go to https://www.t2biosystems.com
and read https://www.t2biosystems.com/world-sepsis/
$TTOO 10 Hours until #worldsepsisday Are you ready?
T2 Biosystems makes great products to fight Sepsis. It
is awaiting FDA & HHS news on new pipeline products.
For accurate DD, go to: https://www.t2biosystems.com
9/13/2023 https://www.t2biosystems.com/world-sepsis/
$TTOO 9 Hours until #worldsepsisday Are you ready?
T2 Biosystems makes great products to fight Sepsis. It
is awaiting FDA & HHS news on new pipeline products.
For accurate DD, go to: https://www.t2biosystems.com
9/13/2023 https://www.t2biosystems.com/world-sepsis/
$TTTO Products to Fight against Sepsis and Bio-Threats
News pending from USFDA on pipeline products. $TTOO
Chairman & Chief Executive Officer Mr. John Sperzel bio.
https://www.t2biosystems.com/our-company/our-team/bio/john-sperzel/
$TTTO Products to Fight against Sepsis and Bio-Threats
News pending from USFDA on pipeline products. $TTOO
Chairman & Chief Executive Officer Mr. John Sperzel bio.
https://www.t2biosystems.com/our-company/our-team/bio/john-sperzel/
$TTOO T2Biosystems Receives New Coverage from Analysts
T2 Biosystems has current & pending products with FDA/HHS
Their products are in the Fight against Sepsis, Bio-threats, etc.
Go to their website: https://www.t2biosystems.com for DD/info.
$TTOO T2Biosystems Receives New Coverage from Analysts
T2 Biosystems has current & pending products with FDA/HHS
Their products are in the Fight against Sepsis, Bio-threats, etc.
Go to their website: https://www.t2biosystems.com for DD/info.
why ?? Sell off probably.
$TTOO in 8/21 Gilmartin Emerging Growth Company Showcase
T2 Biosystems in the Fight against Sepsis. FDA Update pending.
https://www.globenewswire.com/en/news-release/2023/09/07/2739767/32489/en/T2-Biosystems-to-Participate-in-the-Gilmartin-Group-Emerging-Growth-Company-Showcase.html
“LEXINGTON, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE)”
“T2 Biosystems, Inc., (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host
a fireside chat, Thursday September 21, 2023, at 10:30am ET.”
$TTOO in 8/21 Gilmartin Emerging Growth Company Showcase
T2 Biosystems in the Fight against Sepsis. FDA Update pending.
https://www.globenewswire.com/en/news-release/2023/09/07/2739767/32489/en/T2-Biosystems-to-Participate-in-the-Gilmartin-Group-Emerging-Growth-Company-Showcase.html
“LEXINGTON, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE)”
“T2 Biosystems, Inc., (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host
a fireside chat, Thursday September 21, 2023, at 10:30am ET.”
$TTOO T2 Biosystems: Its Products are in the Fight against Sepsis.
$TTOO T2 Biosystems: Its Products are in the Fight against Sepsis.
$TTOO 9/12/23 Annual Shareholders Meeting (in-person & virtual)
“T2 Biosystems has until Nov. 20 for its shares to close at or above $1 for at least 10 consecutive business days but generally no more than 20 consecutive business days” https://www.t2biosystems.com
$TTOO 9/12/23 Annual Shareholders Meeting (in-person & virtual)
“T2 Biosystems has until Nov. 20 for its shares to close at or above $1 for at least 10 consecutive business days but generally no more than 20 consecutive business days” https://www.t2biosystems.com
$TTOO “T2Biosystems: Hot Stock with a Bright Future”
“T2 Biosystems is a medical technology company that develops and markets rapid diagnostic tests for sepsis and other infectious diseases. The company’s products are used in hospitals and other healthcare settings to help doctors diagnose infections quickly and accurately.
T2 Biosystems’ stock has been on a tear in recent months, with the share price more than doubling since the start of the year. The company’s strong financial performance and positive clinical data have been driving the stock’s momentum.
In the first quarter of 2023, T2 Biosystems reported revenue of $21.7 million, up 63% year-over-year. The company also reported a net loss of $10.2 million, but this was narrower than the net loss of $14.2 million in the same quarter of the previous year.
T2 Biosystems’ positive clinical data is also helping to drive the stock’s momentum. In March 2023, the company announced positive top-line results from a late-stage clinical trial of its T2Bacteria panel. The trial showed that the panel was able to detect bloodstream infections caused by bacteria with a high degree of accuracy.
T2 Biosystems is well-positioned for growth in the years to come. The company’s products are in high demand, and the market for rapid diagnostic tests is growing rapidly. T2 Biosystems is also expanding its product portfolio, and the company is developing new tests for other infectious diseases.
Overall, T2 Biosystems is a hot stock with a bright future. The company’s strong financial performance and positive clinical data are fueling its momentum, positioning it well to capitalize on the growing market for rapid diagnostic tests.
Outlook for the Stock
The outlook for T2 Biosystems stock is positive. The company’s strong financial performance and positive clinical data are propelling its stock momentum, positioning it well to seize opportunities in the rapidly growing market for rapid diagnostic tests.
However, there are some risks to consider. The company is still in the early stages of commercialization, and it faces competition from other companies that are developing rapid diagnostic tests. Additionally, the company’s stock is volatile, and it could be susceptible to swings in the market.
Overall, I believe that T2 Biosystems is a good investment for investors who are looking for exposure to the growing market for rapid diagnostic tests. However, investors should be aware of the risks before investing in the company’s stock.”
Source: https://www.livetradingnews.com/t2-biosystems-a-hot-stock-with-a-bright-future-221913.html
$TTOO “T2Biosystems: Hot Stock with a Bright Future”
“T2 Biosystems is a medical technology company that develops and markets rapid diagnostic tests for sepsis and other infectious diseases. The company’s products are used in hospitals and other healthcare settings to help doctors diagnose infections quickly and accurately.
T2 Biosystems’ stock has been on a tear in recent months, with the share price more than doubling since the start of the year. The company’s strong financial performance and positive clinical data have been driving the stock’s momentum.
In the first quarter of 2023, T2 Biosystems reported revenue of $21.7 million, up 63% year-over-year. The company also reported a net loss of $10.2 million, but this was narrower than the net loss of $14.2 million in the same quarter of the previous year.
T2 Biosystems’ positive clinical data is also helping to drive the stock’s momentum. In March 2023, the company announced positive top-line results from a late-stage clinical trial of its T2Bacteria panel. The trial showed that the panel was able to detect bloodstream infections caused by bacteria with a high degree of accuracy.
T2 Biosystems is well-positioned for growth in the years to come. The company’s products are in high demand, and the market for rapid diagnostic tests is growing rapidly. T2 Biosystems is also expanding its product portfolio, and the company is developing new tests for other infectious diseases.
Overall, T2 Biosystems is a hot stock with a bright future. The company’s strong financial performance and positive clinical data are fueling its momentum, positioning it well to capitalize on the growing market for rapid diagnostic tests.
Outlook for the Stock
The outlook for T2 Biosystems stock is positive. The company’s strong financial performance and positive clinical data are propelling its stock momentum, positioning it well to seize opportunities in the rapidly growing market for rapid diagnostic tests.
However, there are some risks to consider. The company is still in the early stages of commercialization, and it faces competition from other companies that are developing rapid diagnostic tests. Additionally, the company’s stock is volatile, and it could be susceptible to swings in the market.
Overall, I believe that T2 Biosystems is a good investment for investors who are looking for exposure to the growing market for rapid diagnostic tests. However, investors should be aware of the risks before investing in the company’s stock.”
Source: https://www.livetradingnews.com/t2-biosystems-a-hot-stock-with-a-bright-future-221913.html
$TTOO Sepsis is a rapidly-progressing, life-threatening immune response triggered by infection that affects millions worldwide each year. Current clinical diagnosis relies on broad physiological parameters and time consuming lab-based cell culture. If proper treatment is not provided, cases of sepsis can drastically increase in severity over the course of a few hours. Development of new point of care tools for sepsis has the potential to improve diagnostic speed and accuracy, leading to prompt administration of appropriate therapeutics, thereby reducing healthcare costs and improving patient outcomes. In this review we examine developing and commercially available technologies to assess the feasibility of rapid, accurate sepsis diagnosis, with emphasis on point of care.
Sepsis is a life-threatening condition caused by the body’s response to microbial infection, which triggers a cascade of events that can lead to organ failure and death.1 Global estimates suggest that there were 31.5 million cases of sepsis in 2016, with 5.3 million resulting in death.2 The Center for Disease Control reports that one in three fatalities in US hospitals are related to sepsis.3 Neonatal sepsis is also a major concern, with the World Health Organization estimating an annual death incidence of over 1 million.4
T2 Biosystems = Products that Fight against Sepsis. For DD, go to:
https://www.t2biosystems.com for Current and Pending Products. A new TTOO Update is currently pending from FDA/HHS at this time.
$TTOO “Sepsis is a rapidly-progressing, life-threatening immune response triggered by infection that affects millions worldwide each year. Current clinical diagnosis relies on broad physiological parameters and time consuming lab-based cell culture. If proper treatment is not provided, cases of sepsis can drastically increase in severity over the course of a few hours.
Development of new point of care tools for sepsis has the potential to improve diagnostic speed and accuracy, leading to prompt administration of appropriate therapeutics, thereby reducing healthcare costs and improving patient outcomes. In this review we examine developing and commercially available technologies to assess the feasibility of rapid, accurate sepsis diagnosis, with emphasis on point of care.
Sepsis is a life-threatening condition caused by the body’s response to microbial infection, which triggers a cascade of events that can lead to organ failure and death.1 Global estimates suggest that there were 31.5 million cases of sepsis in 2016, with 5.3 million resulting in death.2 The Center for Disease Control reports that one in three fatalities in US hospitals are related to sepsis.3 Neonatal sepsis is also a major concern, with the World Health Organization estimating an annual death incidence of over 1 million.4“
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392004/#:~:text=Commercial%20Devices&text=Commercial%20technologies%20currently%20available%20for,molecular%20diagnostics%20and%20mass%20spectroscopy
T2 Biosystems = Products that Fight against Sepsis. For DD, go to:
https://www.t2biosystems.com for Current and Pending Products. A new TTOO Update is currently pending from FDA/HHS at this time.
$TTOO “TTOO developed their T2 Biothreat Testing Panel in conjunction with the U.S. Government, specifically Health and Human Services (HHS). BARDA, a Dept. within HHS recently extended TTOO's $77mil funding award associated with FDA's approval of TTOO's T2 Biothreat Testing Panel. If you do not
realize, the FDA is also a Dept. within HHS. BARDA and the
FDA, both being part of HHS have access to each other. When BARDA extended TTOO's $77mil funding award to Sept 14th,
this Thursday...IMO they had to do it with FDA’s input. Common sense here.” (from ST MPSEnt) https://www.t2biosystems.com
$TTOO “TTOO developed their T2 Biothreat Testing Panel in conjunction with the U.S. Government, specifically Health and Human Services (HHS). BARDA, a Dept. within HHS recently extended TTOO's $77mil funding award associated with FDA's approval of TTOO's T2 Biothreat Testing Panel. If you do not
realize, the FDA is also a Dept. within HHS. BARDA and the
FDA, both being part of HHS have access to each other. When BARDA extended TTOO's $77mil funding award to Sept 14th,
this Thursday...IMO they had to do it with FDA’s input. Common sense here.” (from ST MPSEnt) https://www.t2biosystems.com
$TTOO Increased numbers die in hospitals with sespis per CDC studies https://www.cdc.gov/nchs/products/databriefs/db118.htm
T2 products can detect it quickly https://www.t2biosystems.com/
$TTOO Increased numbers die in hospitals with sespis per CDC studies https://www.cdc.gov/nchs/products/databriefs/db118.htm
T2 products can detect it quickly https://www.t2biosystems.com/
$TTOO Products to fight Sepsis. USFDA news pending.
https://www.independent.co.uk/independentpremium/uk-news/nhs-sepsis-marthas-rule-second-opinion-b2406344.html
Refer to https://www.t2biosystems.com for products, etc.
$TTOO Products to fight Sepsis. USFDA news pending.
https://www.independent.co.uk/independentpremium/uk-news/nhs-sepsis-marthas-rule-second-opinion-b2406344.html
Refer to https://www.t2biosystems.com for products, etc.
$TTOO Sepsis “Lower mortality risk with earlier initiation of targeted antibiotics.” Update from FDA on another TTOO product at anytime.
For DD and facts, go to: https://t2biosystems.com/t2candida-panel/
$TTOO Sepsis “Lower mortality risk with earlier initiation of targeted antibiotics.” Update from FDA on another TTOO product at anytime.
For DD and facts, go to: https://t2biosystems.com/t2candida-panel/
$TTOO To Participate in Gilmartin Group Emerging Growth Co. Showcase (Thur, Sept. 7, 2023 at 4:05 PM EDT) More to follow.
https://www.biospace.com/article/releases/t2-biosystems-to-participate-in-the-gilmartin-group-emerging-growth-company-showcase/
#SEPSIS
$TTOO
$TTOO To Participate in Gilmartin Group Emerging Growth Co. Showcase (Thur, Sept. 7, 2023 at 4:05 PM EDT) More to follow.
https://www.biospace.com/article/releases/t2-biosystems-to-participate-in-the-gilmartin-group-emerging-growth-company-showcase/
#SEPSIS
$TTOO
$TTOO https://investors.t2biosystems.com/static-files/5a1b6ca9-b568-47a0-88ba-1ce02819c9e1 T2Biosystems USFDA/HHS product status any day/time. After updates/news, bring on contracts, moola.
$TTOO https://investors.t2biosystems.com/static-files/5a1b6ca9-b568-47a0-88ba-1ce02819c9e1 T2Biosystems USFDA/HHS product status any day/time. After updates/news, bring on contracts, moola.
$TTOO USFDA/HHS tomorrow? Federal Register Public Inspection
: Notice I Guidance: International Standard ISO 10993-1, Biological Evaluation of Medical Devices, Part 1: Evaluation and Testing within
Risk Management Process” An update published any day, anytime. Go to: https://www.t2biosystems.com/ for TTOO product clearances.
$TTOO USFDA/HHS tomorrow? Federal Register Public Inspection
: Notice I Guidance: International Standard ISO 10993-1, Biological Evaluation of Medical Devices, Part 1: Evaluation and Testing within
Risk Management Process” An update published any day, anytime. Go to: https://www.t2biosystems.com/ for TTOO product clearances.
$TTOO “T2MR AS A RAPID TYPE OF COUNTERMEASURE
TO DIAGNOSE BACTERIAL BIOTHREAT PATHOGENS AND BACTERIAL-ANTIBIOTIC RESISTANCE THREATS”. $TTOO
>>>> https://www.highergov.com/contract/75A50119C00053/
US/FDA,US/HHS, T2Biosystems update any day @ any hour.
$TTOO “T2MR AS A RAPID TYPE OF COUNTERMEASURE
TO DIAGNOSE BACTERIAL BIOTHREAT PATHOGENS AND BACTERIAL-ANTIBIOTIC RESISTANCE THREATS”. $TTOO
>>>> https://www.highergov.com/contract/75A50119C00053/
US/FDA,US/HHS, T2Biosystems update any day @ any hour.
All existing shareholders are going to be bagholders in the case of R/S.
$TTOO CDC's Actions Aimed at Optimizing U.S. Hospitals
Sepsis Programs. TTOO: Right products at the Right Time.
https://research.tdameritrade.com/grid/public/research/stocks/news/article?dockey=100-240u4810-1